fingolimod hydrochloride has been researched along with Polyradiculoneuropathy, Chronic Inflammatory Demyelinating in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (83.33) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Feng, F; Feng, Y; Li, W; Pan, S; Zhang, J | 1 |
| Kanda, T; Koga, M; Maeda, T; Nishihara, H; Okamoto, N; Sano, Y; Shimizu, F; Takeshita, Y; Ueno, M | 1 |
| Agoropoulou, C; Cornblath, D; Dalakas, MC; Ervin, CM; Genge, A; Hartung, HP; Hughes, R; Latov, N; Léger, JM; Merkies, I; Merschhemke, M; Nobile-Orazio, E; Sobue, G | 1 |
| Magy, L | 1 |
| Doneddu, PE; Nobile-Orazio, E | 1 |
| Boehm, N; Brun, S; de Seze, J; Kremer, L; Mensah-Nyagan, AG; Taleb, O; Trifilieff, E | 1 |
1 review(s) available for fingolimod hydrochloride and Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
| Article | Year |
|---|---|
Management of chronic inflammatory demyelinating polyradiculopathy.
Topics: Fingolimod Hydrochloride; Humans; Immunization, Passive; Immunoglobulins, Intravenous; Immunosuppressive Agents; Polyradiculoneuropathy, Chronic Inflammatory Demyelinating; Treatment Failure; Treatment Outcome | 2018 |
1 trial(s) available for fingolimod hydrochloride and Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
| Article | Year |
|---|---|
Oral fingolimod for chronic inflammatory demyelinating polyradiculoneuropathy (FORCIDP Trial): a double-blind, multicentre, randomised controlled trial.
Topics: Administration, Oral; Adrenal Cortex Hormones; Adult; Aged; Disability Evaluation; Double-Blind Method; Electrocardiography; Female; Fingolimod Hydrochloride; Follow-Up Studies; Hand Strength; Humans; Immunoglobulins, Intravenous; Immunosuppressive Agents; Male; Middle Aged; Polyradiculoneuropathy, Chronic Inflammatory Demyelinating; Proportional Hazards Models; Treatment Outcome | 2018 |
4 other study(ies) available for fingolimod hydrochloride and Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
| Article | Year |
|---|---|
Fingolimod ameliorates chronic experimental autoimmune neuritis by modulating inflammatory cytokines and Akt/mTOR/NF-κB signaling.
Topics: Animals; Cytokines; Fingolimod Hydrochloride; Inflammation; Intercellular Adhesion Molecule-1; Interleukin-6; Neuritis, Autoimmune, Experimental; NF-kappa B; Polyradiculoneuropathy, Chronic Inflammatory Demyelinating; Proto-Oncogene Proteins c-akt; Rats; Rats, Inbred Lew; Signal Transduction; TOR Serine-Threonine Kinases; Tumor Necrosis Factor-alpha | 2023 |
Fingolimod promotes blood-nerve barrier properties in vitro.
Topics: Blood-Brain Barrier; Blood-Nerve Barrier; Capillary Permeability; Cell Line; Claudin-5; Endothelial Cells; Fingolimod Hydrochloride; Humans; In Vitro Techniques; Peripheral Nerves; Polyradiculoneuropathy, Chronic Inflammatory Demyelinating; Receptors, Lysosphingolipid; RNA, Messenger | 2018 |
Fingolimod and CIDP: insights from negative results.
Topics: Double-Blind Method; Fingolimod Hydrochloride; Humans; Negative Results; Polyradiculoneuropathy, Chronic Inflammatory Demyelinating | 2018 |
FTY720 controls disease severity and attenuates sciatic nerve damage in chronic experimental autoimmune neuritis.
Topics: Animals; Fingolimod Hydrochloride; Immunosuppressive Agents; Male; Neurites; Neuritis, Autoimmune, Experimental; Polyradiculoneuropathy, Chronic Inflammatory Demyelinating; Rats; Rats, Inbred Lew; Receptors, Lysosphingolipid; Sciatic Nerve; Severity of Illness Index | 2019 |